HQ Science reports that Moderna added $45B in market cap on a cancer vaccine.
Public source
Publisher name
Public post
Moderna added $45B in market cap on a cancer vaccine. Nine days later, BioNTech stopped its own trial. On 19 August, Moderna and Merck reported the first positive Phase…
Company
HQ Science
Get molecular diagnostics within hours, not weeks
- Industry
- Medical and Diagnostic Laboratories
- Location
- Chilton, GB
- Company size
- 2–10 employees
About HQ Science
HQ Science is an Oxford-based MedTech company backed by the UK Health Security Agency, developing a point-of-care molecular diagnostics platform that delivers results in hours instead of weeks. By combining real-time transcriptomic analysis with scalable AI-driven diagnostics, we are enabling faster, more accessible precision medicine across oncology, sepsis, and emergency care, in partnership with leading institutions including the NHS, Oslo University Hospital, and the Oscar Lambret Centre.
See moreLatest activity
Latest activity from HQ Science
6 signals
Research & Knowledge
HQ Science noted that the validation manuscript for the Menopause Impact Scale is still in peer review.
Products & Services
HQ Science distributed the Menopause Impact Scale into ten healthcare partners including Alloy, Gennev, Maven, Tia, Hertility, and five more.
Partnerships
HQ Science partnered with WHOOP to pay for one of the routes into women’s health.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Camelot BioCapital
Camelot BioCapital reported eight deals up to $19 billion in CAR-T and in vivo CAR-T cell therapy, with zero of the eight showing a way to switch the cells off once they're in.
Capital & Finance
Cancer Research Horizons
Cancer Research Horizons leveraged more than £3.5bn in additional investment to support the development of new cancer innovations.
Capital & Finance
Kazia Therapeutics Limited
Kazia Therapeutics Limited announced the oversubscribed closing of a public offering of up to $120 million, generating approximately $40 million in upfront gross proceeds.
Capital & Finance
PDS Biotechnology
PDS Biotechnology announced up to $22.55 million in equity funding in a PIPE transaction in connection with the development of PDS0301 immunocytokine in solid tumors.
Capital & Finance
Labiotech.eu